APTX and metastatic colorectal cancer: In vitro studies of colon cancer cell lines have shown an association between APTX expression levels and sensitivity to camptothecin (Mariadason et al, 2003), and there is also evidence to suggest that APTX modulates response to irinotecan in metastatic colorectal cancer, with higher protein expression associated with a lower likelihood of response.